Abstract
Like many important discoveries in the history of pharmacology, valproate was not developed by any “rational strategy,” but its anticonvulsant activity was serendipitously discovered by Pierre Eymard in France in 1962. Valproic acid (VPA; valproate; di-n-propylacetic acid, DPA; 2-propylpentanoic acid, or 2-propylvaleric acid) was first synthesized in 1882, by Burton [1], but there was no known clinical use until its anticonvulsant activity was fortuitously discovered by Eymard. Because valproic acid is a liquid, it was used as a lipophilic vehicle to dissolve water-insoluble compounds during preclinical drug testing. As part of his thesis in 1962, Eymard had synthesized a number of khelline derivatives in the laboratory of G. Carraz at the School of Medicine and Pharmacy in Grenoble, France [2]. Two colleagues, H. Meunier and Y. Meunier, working for a small company, Berthier Laboratories, in Grenoble, had used valproate for a long time as a vehicle for dissolving of a bismuth salt. So the three scientists Eymard, Meunier and Meunier had the idea to use this vehicle also for dissolving some of the khelline derivatives synthesized by Eymard. In order to evaluate the pharmacological activities of the khelline derivatives, Carraz proposed to test the most active derivative in the pentylenetetrazole (PTZ) seizure test. By doing this, the researchers found that the vehicle, valproate, alone exerted an anticonvulsant effect.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Burton BS (1882) On the propyl derivatives and decomposition products of ethylacetoacetate. Am Chem J3: 385–395
Meunier H, Carraz G, Meunier Y, Eymard P, Aimard M (1963) Propriétés pharmacodynamiques de l’acide n-dipropylacétique. ter Mémoire: Propriétés antiépileptiques. Thérapie 18: 435–438
Carraz G, Darbon M, Lebreton S, Bériel H (1964) Propriétés pharmacodynamiques de l’acide N-dipropylacétique et de ses dérivés. Thérapy 19: 468–476
Lebreton S, Carraz G, Meunier H, Bériel H (1964) Propriétés pharmacodynamiques de l’acide N-dipropylacétique. Deuxième mémoire sur les propriétés antiépileptiques. Thérapie 19: 451–476
Lebreton S, Carraz G, Bériel H, Meunier H (1964) Propriétés pharmacodynamiques de l’acide N-dipropylacétique. Troisième mémoire. Thérapie 19: 457–467
Carraz G, Bériel H, Luu-Duc, Lebreton S (1965) Approches dans la pharmacosynamie biochimique de la structure N-dipropylacétique. Thérapie 20: 419–426
Carraz G, Fau R, Chateau R, Bonnin J (1964) Communication à propos des premiers essais cliniques sur l’activité anti-épileptique de l’acide n-dipropylacétiques (sel de Na). Ann Med Psychol (Paris) 122: 577–585
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Basel AG
About this chapter
Cite this chapter
Löscher, W. (1999). The discovery of valproate. In: Löscher, W. (eds) Valproate. Milestones in Drug Therapy. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8759-5_1
Download citation
DOI: https://doi.org/10.1007/978-3-0348-8759-5_1
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9761-7
Online ISBN: 978-3-0348-8759-5
eBook Packages: Springer Book Archive